Yeast-Derived Extracellular Vesicles for siRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid delivery technologies, such as viral vectors and liposomes, face challenges including immune recognition, inflammation, and mutagenic integration, limiting their broad use for targeted gene silencing, particularly due to rapid clearance and low cellular uptake efficiency.
Innovation Solution
Development of Saccharomyces-generated extracellular vesicles (EVs) containing foreign RNA molecules or proteins that specifically bind to target cells, utilizing a Saccharomyces cerevisiae or Saccharomyces boulardii-derived EVs platform for targeted gene silencing, particularly using small interfering RNA (siRNA) delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used for nucleic acid delivery, then delivery efficiency is improved, but immune recognition and inflammation occur
Solution Approach 1:
The patent employs extracellular vesicles (EVs) as a delivery vehicle that is naturally produced by yeast cells and does not trigger immune responses. EVs are non-viral, non-mutagenic alternatives that can be rapidly produced and cleared without causing the harmful immune effects associated with viral vectors, while maintaining effective nucleic acid delivery capability.
Solution Approach 2:
The patent uses extracellular vesicles as an intermediary carrier between the nucleic acid payload and target cells. These EVs mediate the delivery process by providing a biocompatible vehicle that avoids direct immune recognition, allowing the therapeutic nucleic acids to reach target cells without triggering inflammatory responses.
2Productivity
If liposomes are used for nucleic acid delivery, then delivery capability is improved, but rapid clearance and low cellular uptake occur
Solution Approach 1:
The patent changes the fundamental parameters of the delivery vehicle by using extracellular vesicles instead of liposomes. EVs have different biophysical properties including smaller size, natural membrane composition, and enhanced cellular uptake mechanisms that prevent rapid clearance while improving delivery reliability to target cells.
Solution Approach 2:
The patent employs extracellular vesicles as a biocompatible delivery vehicle that is naturally produced by yeast cells and does not trigger immune responses. EVs are non-viral, non-mutagenic alternatives that can be rapidly produced and cleared without causing the harmful immune effects associated with viral vectors, while maintaining effective nucleic acid delivery capability.
3Measurement precision
If engineered EVs are generated for targeted delivery, then specificity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent segments the EV generation process into modular components: yeast cell culture, EV isolation, ligand conjugation, and quality control. This segmentation allows for standardized, scalable production while maintaining targeted delivery specificity through controlled conjugation of targeting ligands to EV surfaces.
Solution Approach 2:
The patent uses extracellular vesicles as an intermediary carrier between the nucleic acid payload and target cells. These EVs mediate the delivery process by providing a biocompatible vehicle that avoids direct immune recognition, allowing the therapeutic nucleic acids to reach target cells without triggering inflammatory responses.
Data Source
AI summary
Saccharomyces-generated extracellular vesicles (EVs) comprising a foreign RNA molecule or protein, and method of using the same.